Terms: = Leukemia AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Clinical Outcome
9 results:
1. Dual inhibition of stat3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K
Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
[TBL] [Abstract] [Full Text] [Related]
2. Phosphorylated stat3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.
Morichika K; Karube K; Kayo H; Uchino S; Nishi Y; Nakachi S; Okamoto S; Morishima S; Ohshiro K; Nakazato I; Fukushima T; Masuzaki H
Cancer Sci; 2019 Sep; 110(9):2982-2991. PubMed ID: 31237072
[TBL] [Abstract] [Full Text] [Related]
3. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract] [Full Text] [Related]
4. Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway.
Liu K; Wu Z; Chu J; Yang L; Wang N
Biomed Pharmacother; 2019 Jul; 115():108913. PubMed ID: 31054507
[TBL] [Abstract] [Full Text] [Related]
5. Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.
Wang HQ; Jia L; Li YT; Farren T; Agrawal SG; Liu FT
J Cell Physiol; 2019 Aug; 234(8):13994-14006. PubMed ID: 30623437
[TBL] [Abstract] [Full Text] [Related]
6. Donor-Derived T-Cell Large Granular Lymphocytic leukemia in a Patient With Peripheral T-Cell Lymphoma.
Hidalgo Lopez JE; Yabe M; Carballo-Zarate AA; Wang SA; Jorgensen JL; Ahmed S; Lee J; Li S; Schlette E; McDonnell T; Miranda RN; Medeiros LJ; Bueso-Ramos CE; Yin CC
J Natl Compr Canc Netw; 2016 Aug; 14(8):939-44. PubMed ID: 27496109
[TBL] [Abstract] [Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
Folgiero V; Goffredo BM; Filippini P; Masetti R; Bonanno G; Caruso R; Bertaina V; Mastronuzzi A; Gaspari S; Zecca M; Torelli GF; Testi AM; Pession A; Locatelli F; Rutella S
Oncotarget; 2014 Apr; 5(8):2052-64. PubMed ID: 24903009
[TBL] [Abstract] [Full Text] [Related]
8. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.
Piazza F; Manni S; Semenzato G
Leuk Res; 2013 Feb; 37(2):221-7. PubMed ID: 23174190
[TBL] [Abstract] [Full Text] [Related]
9. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract] [Full Text] [Related]
